# Eisai Korea Inc. clinical trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Eisai Korea Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eisai Korea Inc.: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eisai-korea-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 9, 2025 | NCT06964113 | A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | Eisai Korea Inc. | Phase 4 | Active not recruiting | Ulcerative Colitis | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06964113) |
| February 6, 2025 | NCT06810960 | A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease | Eisai Korea Inc. | Observational | Recruiting | Alzheimer's Disease | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810960) |
| October 3, 2024 | NCT06625242 | A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis | Eisai Korea Inc. | Phase 4 | Completed | Rheumatoid Arthritis | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625242) |
| February 7, 2024 | NCT06246123 | A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | Eisai Korea Inc. | Observational | Recruiting | Arthritis, Rheumatoid, Colitis, Ulcerative | 2,040 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246123) |
| September 9, 2022 | NCT05533814 | A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without... | Eisai Korea Inc. | Phase 4 | Completed | Epilepsy | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533814) |
| May 16, 2022 | NCT05375136 | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | Eisai Korea Inc. | Observational | Completed | Endometrial Neoplasms, Endometrium, Carcinoma, Renal Cell Carcinoma | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05375136) |
| May 9, 2022 | NCT05366036 | A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis | Eisai Korea Inc. | Observational | Completed | Multiple Sclerosis, Relapsing-remitting | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05366036) |
| April 5, 2022 | NCT05312632 | A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With... | Eisai Korea Inc. | Phase 4 | Completed | Parkinson Disease | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05312632) |
| February 4, 2022 | NCT05225324 | A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg) | Eisai Korea Inc. | Observational | Completed | Parkinson Disease | 702 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05225324) |
| February 4, 2022 | NCT05225207 | A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants | Eisai Korea Inc. | Observational | Completed | Liver Neoplasms, Carcinoma, Hepatocellular | 658 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05225207) |
| January 26, 2022 | NCT05208268 | A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and... | Eisai Korea Inc. | Observational | Completed | Stomach Ulcer, Duodenal Ulcer | 676 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208268) |
| February 28, 2018 | NCT03448445 | A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a... | Eisai Korea Inc. | Observational | Completed | Mild Cognitive Impairment | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03448445) |
| February 19, 2018 | NCT03437083 | A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | Eisai Korea Inc. | Observational | Completed | Locally Advanced or Metastatic Breast Cancer | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03437083) |
| August 29, 2017 | NCT03264703 | Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying... | Eisai Korea Inc. | Observational | Completed | Arthritis, Rheumatoid | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03264703) |
| August 29, 2017 | NCT03264690 | Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF... | Eisai Korea Inc. | Observational | Completed | Inflammatory Bowel Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03264690) |
| May 6, 2016 | NCT02764554 | Post-Marketing Surveillance of Lenvima in Korean Patients | Eisai Korea Inc. | Observational | Completed | Differentiated Thyroid Carcinoma (DTC) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02764554) |
| April 1, 2016 | NCT02726074 | Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without... | Eisai Korea Inc. | Phase 4 | Completed | Epilepsy | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02726074) |
| March 30, 2016 | NCT02722590 | A Study of Fycompa (Perampanel) in Korean Participants | Eisai Korea Inc. | Observational | Completed | Epilepsy | 3,692 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02722590) |
| May 12, 2015 | NCT02441764 | Halaven Post-Marketing Surveillance (PMS) | Eisai Korea Inc. | Observational | Completed | Breast Cancer | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02441764) |
| May 5, 2015 | NCT02434484 | Symbenda Post-Marketing Surveillance (PMS) | Eisai Korea Inc. | Observational | Completed | Lymphoma, Non-Hodgkin, Lymphocytic Leukemia, Multiple Myeloma | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02434484) |
| October 13, 2014 | NCT02262975 | A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed... | Eisai Korea Inc. | Observational | Completed | Alzheimer's Disease | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02262975) |
| June 9, 2014 | NCT02158910 | A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients | Eisai Korea Inc. | Observational | Completed | Alzheimer's Disease | 2,231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02158910) |
| March 26, 2014 | NCT02097056 | Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease | Eisai Korea Inc. | Phase 4 | Completed | Alzheimer's Disease | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02097056) |
| October 11, 2013 | NCT01961544 | Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer | Eisai Korea Inc. | Phase 4 | Completed | Breast Neoplasms, Breast Cancer | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01961544) |
| June 10, 2010 | NCT01140867 | Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy | Eisai Korea Inc. | Phase 4 | Completed | Epilepsy | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01140867) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 4 | 14 |
| Observational | 17 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Recruiting | 2 |
| Active not recruiting | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Alzheimer Disease | 8 |
| Epilepsy | 7 |
| Arthritis, Rheumatoid | 3 |
| Colitis, Ulcerative | 3 |
| Breast Neoplasms | 3 |
| Parkinson Disease | 2 |
| Neoplasm Metastasis | 2 |
| Cognitive Dysfunction | 1 |
| Liver Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Arthralgia | 1 |
| Inflammatory Bowel Diseases | 1 |
| Crohn Disease | 1 |
| Epilepsy, Idiopathic Generalized | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Multiple Sclerosis | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Leukemia, Lymphoid | 1 |
| Multiple Myeloma | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Seizures | 1 |
| Stomach Ulcer | 1 |
| Duodenal Ulcer | 1 |
| Endometrial Neoplasms | 1 |
| Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Oncology practices in the United States](https://specstream.ai/data/businesses/oncology-practices/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
